



Introduction: The study of cardiac response to strenuous and continuous exercise is crucial to understanding the physiology of endurance. N-ter-
minal proB-type natriuretic peptide (NT-proBNP) is a potential marker for monitoring myocardial wall stress, and troponins (TnT and TnI) are widely 
used in the diagnosis of cardiac ischemia and infarction. Strenuous exercise may generate transitory ischemia, myocardial stress, and diastolic left 
ventricular dysfunction, inducing the increased production of both these biomarkers. We measured changes in NT-proBNP and TnT in elite cyclists 
during a 3-week stage race, a model of strenuous exercise.
Materials and methods: The study population was 9 professional cyclists participating in the 2011 Giro d’Italia. Pre-analytical and analytical pha-
ses scrupulously followed offi  cial recommendations. Anthropometric data, net energy expenditure and cardiac indexes (rate, diastolic and systolic 
blood pressure) were recorded. Blood samples were drawn pre-race (day -1) and at days 12 and 22; NT-proBNP and highly sensitive-troponin (Hs-
TnT) concentrations were assayed and corrected for plasma volume changes.
Results: Body-mass index decreased and energy expenditure increased by 52% during the race. NT-proBNP concentrations increased [day -1: 23.52 
ng/L (9.67-34.33); day 12: 63.46 ng/L (22.15-93.31); P = 0.039; day 22: 89.26 ng/L (34.66-129.78) vs. day -1; P < 0.001] and correlated with heart rate 
(r = -0.51; P = 0.006), systolic pressure (r = 0.39; P = 0.046) and energy expenditure (r = 0.70; P < 0.001). TnT concentrations did not vary, but a 
widened TnT amplitude distribution was observed.
Conclusions: Increases in NT-proBNP correlated with higher energy expenditure over a 3-week cycling stage race, possibly indicating myocardial 
stress.
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The 76 amminoacid N-terminal proB-type natriu-
retic peptide (NT-proBNP) has been proposed as a 
marker for evaluating and monitoring cardiac ab-
normalities characterized by myocardial wall stress 
(1). Strenuous exercise may generate transitory 
ischemia, myocardial stress, and diastolic left ven-
tricular dysfunction, resulting in increased produc-
tion of NT-proBNP suggestive of incipient heart 
disease.
Increased NT-proBNP levels after physical exercise 
in endurance athletes (2,3) and after heavy physi-
cal exercise in professional athletes has been de-
scribed (4,5). In appropriately trained athletes, the 
production of this peptide is lower at rest and ex-
ercise-induced increases remain below abnormal 
limits (6,7). NT-proBNP concentrations in rugby 
players, for example, were not substantially aff ect-
ed by post-training recovery (passive, active recov-
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ery followed by cold-water immersion, cold-water 
immersion followed by active recovery) (6).
The rationale for the use of NT-proBNP, instead of 
mature BNP, as marker for cardiac dysfunction re-
sides in their diff erent half-life (90-120 versus 18 
min) (8). The fi nding that NT-proBNP, but not intact 
BNP is augmented after endurance sport perfor-
mance (9) is a consequence of the diff erent life 
spans of the molecules.
Exercise-induced production of NT-proBNP needs 
to be distinguished from abnormal increases due 
to heart damage. NT-proBNP is a reliable diagnos-
tic and prognostic marker in patients with suspect-
ed heart failure. Chronic elevations, along with 
those of other natriuretic peptides, aid in identify-
ing and monitoring cardiac dysfunction. Diff erent-
ly, exercise-induced NT-proBNP changes, particu-
larly in well-trained professional athletes, refl ect 
an acute response to altered hemodynamics, re-
gional wall-motion abnormalities, and exercise-in-
duced transitory myocardial wall ischemia (10). 
Furthermore, exercise-induced NT-proBNP pro-
duction in such athletes very likely stems from a 
cytoprotective mechanism (2,11).
The mechanism underlying its release has not 
been elucidated. Systemic infl ammation following 
strenuous exercise may stimulate the release of 
NT-proBNP into the circulation (11).
Cardiac damage was inferred from high NT-proB-
NP concentrations measured in 60 non-profession-
al athletes after a marathon (7): 60% of the recre-
ational runners had increased troponin T (TnT) and 
NT-proBNP levels; left ventricular size and ejection 
fraction were unchanged but left ventricular com-
pliance was reduced; changes in biochemical signs 
of cardiac damage were more pronounced in the 
runners who had trained at low training work-
loads. The study results serve as a reminder that 
appropriate preparation is mandatory to protect 
athletes against potentially harmful elevation of 
cardiac biomarkers and the risk of cardiac dysfunc-
tion associated with endurance performance (7).
Troponins (T and I) are commonly used diagnostic 
markers for cardiac ischemia and infarction. Their 
relevance for sports medicine was highlighted in a 
recently published critical review of studies on in-
creased troponin levels after prolonged strenuous 
physical activity (12). With the advent of assays 
with high analytical sensitivity, also known as high-
ly sensitive troponin (Hs-Tns) tests, the negative 
predictive value of troponin testing has improved, 
but its clinical specifi city has substantially de-
creased (13).
Evaluating Tns release after prolonged strenuous 
exercise poses a challenging problem for clinical 
chemistry. Several hypotheses have sought to ex-
plain the release of cardiac proteins, focusing 
mainly on increased membrane permeability and 
leakage of the unbound cytosolic pool, which 
comprises only a small part of the total pool of car-
diac Tns (14). Tns loss due to higher membrane 
permeability and the formation of “blebs” (15), i.e., 
membrane evaginations possibly providing the 
pathway for protein release, could explain the co-
existence of serum Tns in a disease state and in the 
absence of myocardial dysfunction (16). Transient 
ischemia, which may occur during exercise, would 
not normally be suffi  cient to induce irreversible 
membrane injury: the blebs are reabsorbed or re-
leased into the circulation, where low and short-
lasting amounts of Tns detectable with the new 
highly sensitive assays can be measured. In perma-
nent damage, due to lack of reoxygenation, the 
blebs collapse and are not shed into circulation; 
subsequently, high amounts of Tns are released, 
with myocell necrosis and lysis, a feature typical of 
myocardial infarction.
Numerous studies utilizing last-generation Tns as-
says have been performed on athletes: runners (21 
studies); triathletes (one study); and basketball 
players (one study) (12). Only one study involved 
91 non-professional cyclists participating in a cy-
cle-touring event (206 km) (17); in 43% of the cy-
clists, TnI exceeded the upper reference limit (URL) 
already at 20 min post-exercise.
Biomarkers for cardiac overload and damage have 
been studied in single, one-day, and ultraendur-
ance events. A study published in 1996 and involv-
ing endurance athletes in a prolonged stage race 
used a now outmoded TnT assay which was aff ect-
ed by interference from skeletal muscle proteins. 
However, cardiac TnT (cTnT) was found in the se-
rum of only 5 athletes, repeatedly in some cases, 
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but always below the cut-off  values for myocardial 
ischemia. On the basis of the behaviour of creatine 
kinase isoenzyme MB and, above all, of cTnT, it was 
concluded that heavy-endurance exercise repeat-
ed daily for 22 days was unable to induce perma-
nent heart damage by acute myocardial injury in 
top athletes (18).
The study of biochemical parameters of cardiac 
damage is crucial for defi ning their behaviour after 
endurance, strenuous and continuous exercise 
and to avoid misinterpreting elevated serum lev-
els. Equally important is setting cut-off  values in 
endurance athletes to avert misrecognition of 
signs of myocardial overload or frank pathology.
Evaluating cardiac response is essential for improv-
ing our understanding of the physiology of endur-
ance. Here we report on the changes in NT-proBNP 
and Hs-TnT in relation to energy expenditure in 
professional athletes during a 3-week staged cy-




This prospective, non-comparative interventional 
study involved 9 professional cyclists from the Liq-
uigas-Cannondale professional cycling team. All 
subjects had participated in the 2011 Giro d’Italia 
and were followed during the duration of the race 
from 8 through 29 May 2011.
The mean completion time for the cyclists was 
86:47:29 h (range, 84:12:10-88:15:51 h) with a mean 
speed of 35.7 km/h. The median age was 26 years 
(range, 24–33). Height, weight and body-mass in-
dex (BMI) were measured the morning before the 
start of each stage under fasting and rest condi-
tions (Table 1). Diet was strictly controlled by team 
physicians.
Three subjects received non-steroidal anti-infl am-
matory drugs (NSAIDs) and antibiotics for an up-
per respiratory tract infection for 5 days during the 
fi rst week (one case) and during the second week 
(two cases). The 2011 Giro d’Italia was a “no-nee-
dle” race in which therapies and drugs were per-
mitted only for evident illness.
Blood drawings were performed on the day before 
the start (day -1), on the 12th day (day 12), and on 
the fi nal day of the race (day 22) (Figure 1).
The total net energy expenditure (kcal) for each 
stage was derived from the developed power 
measured with a power sensor (PowerMeter™, SRM 
GmbH, Jülich, Germany) incorporated into the bike 
pedal (sensitivity ± 2%). The measures taken dur-
ing the race are relative to the day before the 
blood drawings to allow the determination of cor-
relation.
The study design and protocol were approved by 
the reference ethical committee (ASL Città di Mi-
lano); informed consent was obtained from all sub-
jects before the beginning of the study.
Methods
Blood drawings
Adherence to pre-analytical recommendations 
was strictly observed to prevent factors from inad-
vertently aff ecting the analytical data. The Union 
Cycliste Internationale (UCI) and World Anti-Dop-
ing Agency (WADA) rules for collection and trans-
port of specimens were followed (19,20).
Blood drawing was performed between 08.00 hrs 
and 10.00 hrs after overnight fasting with subjects 
resting in bed for 10 minutes after awaking.
Parameter day -1 day 12 day 22 P value
Height (m) 1.83 (1.74-1.86) / / /
Weight (kg) 67.0 (63.1-75.9)§ 66.5 (63.7-76.0)§ 65.5 (61.6-73.4)* 0.023
BMI (kg/m2) 20.9 (19.3-22.5)§ 20.8 (19.5-22.4)§* 20.9 (19.0-21.5)* 0.019
TABLE 1. Anthropometrical measurements recorded at the three time-points. Measurements are expressed as median and distribu-
tion range (5th – 95th percentile). The diff erent superscripts denote statistical signifi cance at P < 0.05.
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Evacuated tubes (BD Vacutainer Systems, Becton-
Dickinson, Franklin Lakes, NJ, USA) were used for 
the haematological tests (BD K2EDTA 3.5 mL tubes); 
7 mL plain tubes (BD SSTII Advance) were used for 
clinical chemistry tests. Immediately after blood 
drawing, the tubes were inverted 10 times and 
stored in a sealed box at 4 °C. Controlled tempera-
ture was assured during transport: a specifi c tag 
(Libero Ti1, Elpro, Buchs, Switzerland) was used for 
temperature measurement and recording. The 
samples were transported by car or train and car: 
the time elapsed between blood drawing and ar-
rival at the laboratory was 1.30 hrs on day -1, 7.50 
hrs on day 12, and 1.30 hrs on day 22. After arrival 
at laboratory, the K2EDTA-anticoagulated blood 
was homogenized for a minimum of 15 min with 
an appropriate mixer prior to analysis, as recom-
mended by the UCI Blood Analytical Protocol (Jan-
uary 2009) and the Athlete Biological Passport Op-
erating Guidelines WADA (January 2010) (19,20). 
Plain tubes were immediately centrifuged 1300 x g 
at 4 °C for 10 min and the serum was stored at -80 
°C until analysis.
Cardiac indexes
Resting heart rate and diastolic and systolic pres-
sure were measured in the morning with the sub-
jects resting in bed immediately after awakening. 
The measurements were performed in duplicate 
at the wrist with an OMRON R3™ (Omron Health-
care Co. Ltd, Kyoto, Japan).
Calculation of plasma volume changes
Repeated measurement of blood parameters in 
humans during and after physical activity is infl u-
enced by changes in plasma volume (21). The per-
centage variation in plasma volume (∆PV%) at con-
secutive time-points was calculated according to 
the formula (21):
∆PV%= 100 x [(Hbpre / Hbpost) x (1-Htpos t/ 100)/
(1-Htpre / 100)] - 100;
where Hbpre and Hbpost are the pre- and the post-
intervention haemoglobin (Hb) concentration, re-
spectively, and Htpre and Htpost are the pre- and 
the post-intervention haematocrit (Ht) percentag-
es, respectively.
The analyte concentrations measured at days 12 
and 22 were corrected for relative changes in PV% 
using the following equation:
Corrected values = uncorrected values x
[100-∆PV(%)] / 100
Measurement of cardiac biomarkers
NT-proBNP and Hs-TnT levels were measured on a 
Roche Modular Analytics EVO analyzer (Roche Di-
agnostics, Lewes, Sussex, UK) with Elecsys® proB-
NP and Elecsys® Hs-TnT, respectively. Both meth-
ods are based on sandwich immunodetection.
Serum NT-proBNP measurement had an analytical 
range of 5-35,000 ng/L, an inter-assay coeffi  cient 
of variation (CV) of 0.7 to 1.6%, and an intra-assay 
CV of 5.3 to 6.6%. Serum Hs-TnT measurement had 
an inter-assay CV of 8% at 10 ng/L and 2.5% at 100 
ng/L, and an intra-assay CV of 5% at 10 ng/L and 
1% at 100 ng/L. The analytical range of this assay is 
2 to 10,000 ng/L.
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism® ver. 5.0 (GraphPad Software, La Jolla, CA, 
Stage Lenght (Km)
Level difference (m)
96 780 2340 2779 3637 3200 2796 912 5412
19.3 244 173 216 191 216 110 217 196 /
/
159 144 184 167 210 229 / 12.7 230 151 209 242 31.5
882 3097 463 4664 6643 9490 / 756 5336 1949 3569 3464 67
Day –3 –2 –1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
R R
FIGURE 1. Race features. The diagram illustrates length (km) and diff erence in elevation (m) of each stage, day of each stage, days of 
rest (R), day of blood sampling for this study ( ), and day of blood sampling for offi  cial anti-doping testing (∆).
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USA). All values in the descriptive analysis are ex-
pressed as median and distribution range (5th-95th 
percentile). Friedeman’s test was used to compare 
values over time with Dunn’s post-hoc test. The 
widening in TnT amplitude distribution was evalu-
ated by the Levene’s test. Correlation analysis be-
tween the measured parameters was performed 
using the two-tailed Spearman’s rank correlation 
test. Signifi cance was set at P < 0.05.
Results
Anthropometrical measurements
There was a signifi cant decrease in both body 
weight and BMI during the race. At day 22, weight 
signifi cantly diff ered from that measured at day -1 
and day 12, while BMI was signifi cantly lower than 
at day -1 (Table 1).
Except for the baseline values, the energy expen-
diture was calculated for the days before the blood 
drawings to evaluate a possible relationship be-
tween the previous metabolic eff ort and the con-
sequent physiological response.
A signifi cant diff erence in net energy expenditure 
between the three time-points was seen. Energy 
expenditure increased by about 21% between the 
rest values and day 12 (P = 0.039), 39% between 
days 12 and 22 (P = 0.008), and 52% between days 
-1 and 22 (P < 0.001) (Figure 2). The increase ob-
served at day 21 was related to the diff erences in 
topographic elevation during the second half of 
the race: the fi rst part of the race was composed of 
5 plain stages, 3 middle-high mountain stages, 
and 2 high-mountain stages (total diff erence in el-
evation 21,952 m); the second part was composed 
of 3 plain stages, 3 middle-high mountain stages, 
and 5 high-mountain stages (total diff erence in el-
evation 40,313 m) (Figure 1).
Cardiac indexes
Resting heart rate and systolic and diastolic blood 
pressure values remained unchanged during the 
race.
Changes in plasma volume
As calculated with the Dill & Costill formula (21), no 
signifi cant changes in plasma volume were ob-
served during the race. Descriptively, the median 
PV% increased in the fi rst part of the race (day -1 to 
day 12) by 1.55% (0.45-3.34) and decreased in the 
second part by -0.72% (-1.95-0.80) (day 12 to day 
22). The net increase in PV between days -1 and 22 
was 0.99% (-0.86-2.34).
The changes in PV paralleled those in both [Hb] 
and Ht, which did show signifi cant variations dur-
ing the race. [Hb] decreased from day -1 [146 g/L 
(137-154)] to day 12 [131 g/L (127-142)] (P = 0.031) 
but did not signifi cantly increase between days 12 
and 22 [133 g/L (127-150)]; the net variation over 
baseline to the end of the race was signifi cant (P = 
0.004).
The same trend was observed for Ht: a decrease 
from day -1 [42.7% (40.8-44.8)] to day 12 [39.2% 
(37.8-42.1); P = 0.009], followed by an insignifi cant 
increase from day 12 to day 22 [39.8% (37.8-44.0)]; 
the net variation over baseline to the end of the 
race was signifi cant (P = 0.010).
Biomarker analysis
Serum NT-proBNP increased signifi cantly over 
baseline from 23.52 ng/L (9.67-34.33) at day –1 to 
63.46 ng/L (22.15-93.31) at day 12 (P = 0.039) and to 







Day –1 Day 11 Day 21
Net Energy Expenditure
FIGURE 2. Net energy expenditure during the race. The graph 
shows the total net energy expenditure at baseline (day -1) 
and the days before the following blood drawings (day 11 and 
day 21). Triangles denote the individual concentrations of the 
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No diff erences were found in serum Hs-TnT levels: 
3.00 ng/L (3.00-3.88) ng/L at day -1; 3.34 ng/L (3.00-
9.33) ng/L at day 12; and 4.26 ng/L (3.00-21.90) 
ng/L at day 22. However, there was a signifi cant 
widening in the amplitude distribution of the val-
ues from day -1 to day 22 (P < 0.001). Figure 3 re-
ports the trend for the cardiac biomarker concen-
trations.
A fairly positive correlation was found between 
NT-proBNP and Hs-TnT levels (r = 0.44, P = 0.022).
When NT-proBNP concentrations were corrected 
for ∆PV% changes, the signifi cance was kept but 
their levels were found to increase: day -1 vs. day 
12 (P < 0.001); day -1 vs. day 22 (P < 0.001) and day 
12 vs. day 22 (P = 0.008). The PV% change did not 
aff ect the TnT concentrations.
A moderately signifi cant negative correlation was 
also found between BMI and NT-proBNP concen-
tration (r = -0.54, P = 0.004) but not between BMI 
and TnT concentration (r = -0.25, P = 0.199).
No correlations were found between either bi-
omarker concentration and PV%; however, while 
there was a fairly signifi cantly correlation between 
the percentage variation in NT-proBNP concentra-
tion and the ∆PV% across the time-points (r = 0.47, 
P = 0.015), no such correlation was seen for TnT 
concentration (r = -0.08, P = 0.694).
There was a signifi cant and moderately negative 
correlation between NT-proBNP and heart rate (r = 
-0.51, P = 0.006) but not between heart rate and 
TnT (r = -0.19, P = 0.348).
NT-proBNP concentrations fairly correlated with 
systolic pressure (r = 0.39, P = 0.046) but not with 
diastolic pressure (r = 0.32, P = 0.081).
Interestingly, there was a signifi cant correlation 
between NT-proBNP and net energy expenditure 
(r = 0.70, P < 0.001) and a fairly signifi cant correla-
tion with TnT (r = 0.39, P = 0.013).
Discussion
NT-proBNP levels increased signifi cantly during 
the 3-weeks stage race and were accompanied by 
a widening of the standard deviation, with high 
inter-individual variability, particularly after heavy 
and strenuous endurance exercise in these ath-
letes, as observed previously (3,7,22). Increased NT-
proBNP may be interpreted as a possible sign of 
transitory heart damage and a potential risk for 
both professional and recreational athletes alike 
(23). Reports of abnormally high post-race NT-
proBNP concentrations (182 ng/L) in non-profes-
sional marathoners highlight the potentially dan-
gerous eff ects of endurance performance on the 
heart. However, the starting median one study 
found in non-professional athletes was already 
high (106 ng/L), inevitably aff ecting interpretation 
of the data (7). Resting NT-proBNP values in mara-
thoners (28.8 and 44 ng/L) (5, 22), mountain mara-
thoners (39.7 ng/L) (4) and the pre-race values in 
our cyclists were within the reference limits for the 
general population (24). These cyclists were well-
Day –1


















FIGURE 3. Changes in serum cardiac markers during the race. 
The graph shows the trend for concentrations of NT-proBNP 
(panel A) and Hs-TnT (panel B). *: P < 0.05, **: P < 0.001.
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trained professional athletes capable of withstand-
ing high, specifi c workloads; therefore, despite 
continuous stimulation of heart wall, the stable, 
low values could be considered a typical feature of 
their physiological condition.
Our data are in line with those obtained in 20 en-
durance athletes (10 triathletes, 5 cyclists, 5 mara-
thoners) (median concentration of 24.7 ng/L versus 
28.9 ng/L in the controls) (2). Low NT-proBNP con-
centrations were also found in 50 professional cy-
clists (mean of 23.6 ng/L versus 36.3 ng/L in 35 sed-
entary subjects) (10).
Strenuous physical exercise increases the produc-
tion of NT-proBNP in professional athletes. The 
end-race values we found were similar to those re-
ported after a mountain marathon (median of 97.6 
ng/L) (9) and a marathon (150.2 ng/L) (3). Such in-
creases could result from the repeated release of 
NT-proBNP which, because of continuous and 
stressful exercise, is not completely recovered. Fol-
lowing a bout of 3-hour long exercise in trained 
subjects, NT-proBNP increased from 19 to 49 ng/L 
and then fell to 38 ng/L within 3 hours after the 
end of the exercise (2). In the present study, the re-
lease of NT-proBNP may have been constant dur-
ing the race: gradual recovery was possible during 
the easier fi rst part but was hindered by the much 
more diffi  cult second part (diff erences in elevation 
of 21,952 m versus 40,313 m). This is confi rmed by 
the strong correlation between the trends for NT-
proBNP concentration and energy expenditure as 
a measure of physical eff ort.
No data exist about NT-proBNP behaviour in pro-
fessional cyclists. One study involving 29 recrea-
tional cyclists during the 2004 Ötztal Radmarathon 
evaluated NT-pro-BNP. NT-proBNP signifi cantly in-
creased from 28 ± 21 to 278 ± 152 ng/L immedi-
ately after the race, and then decreased the follow-
ing day before returning to baseline values 1 week 
later (25). Diff erences between professional and 
non-professional athletes aside, the dramatic in-
crease in the biomarker in these recreational ath-
letes is evident. Because of its typical release kinet-
ics, the authors attributed the decrease in NT-pro-
BNP to an adequate volume regulatory response 
of a hemodynamically stressed heart to prolonged 
strenuous exercise.
A bimodal increase in NT-proBNP was reported in 
10 trained male cyclists (age, 40.0 ± 4.5 years) who 
simulated the 2007 Tour de France. After the third 
stage of the race simulation, NT-proBNP increased 
up to 200 ng/L, returned to 50 ng/L at stage 12, 
before increasing again to about 250 ng/L at stage 
17 (26). It should be remarked that the rise in NT-
proBNP was linked to impaired diastolic function 
causing residual diastolic ventricular fi lling. Systolic 
function, represented primarily by global and seg-
mental ejection fractions, was not aff ected until 
about stage 9, after which the values stabilized or 
rose slightly. A direct connection with cardiac bi-
omarkers was not observed (26). In our sample of 
professional cyclists, although cardiac function did 
not change during the race, a mild but signifi cant 
correlation was found between NT-proBNP and 
both heart rate (negatively) and systolic pressure 
(positively).
Increased NT-proBNP during and after exercise is 
linked to the growth-regulating properties of BNP, 
which regulates myocardial adaptation in healthy 
athletes (2) and is physiologically induced by sys-
temic infl ammatory cytokines (11) rather than be-
ing a clear and undoubted sign of heart damage, 
which rarely occurs (27).
Troponin release after exercise, especially after en-
durance events, has been reported mostly in run-
ners and marathoners. Exercise-induced cTnT re-
lease was apparent in almost half of endurance 
athletes according to a meta-analysis of 26 rele-
vant studies (1120 cases) (28).
The interpretation of elevated Tns is undefi ned. 
Current guidelines for the identifi cation of acute 
myocardial infarction are based on positive serum 
troponin values. However, a number of studies 
have reported positive values for cTnT levels in 
asymptomatic, healthy subjects after endurance 
exercise, suggesting that positive cTnT values can 
result after strenuous exercise (29). The introduc-
tion in laboratory routine of highly sensitive assays 
for cTnT has increased the possibility of their mis-
classifi cation: while these tests have higher analyt-
ical sensitivity (i.e., low limit of detection) and a 
higher negative predictive value of troponin, their 
clinical specifi city is lower (12). The reference pop-
ulation where the 99th percentile limit of the refer-
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ence value distribution (99th URL) obtained with 
assays having a coeffi  cient of variation < 10% at 
those levels must be accurately selected for ob-
taining clinically valid data (30).
There are few studies on Hs-TnT levels in athletes. 
After a marathon, Hs-TnT was higher than the URL 
(0.016 μg/L) in 86% of 70 male and 15 female ama-
teur runners (age range, 45-49 years) (31). In anoth-
er study on 10 male amateur marathoners with a 
similar age range, Hs-TnT was higher than the URL 
(0.012 μg/L) after an ultramarathon of 216 km, but 
unexpectedly, the percentage of positivity imme-
diately after the race was lower than that described 
after a classical marathon (40%) (32).
A similar positive percentage after a classical mara-
thon was, however, reported in amateur male run-
ners by using the lowest URL (0.010 μg/L; 43%) (33). 
After a marathon, Hs-TnT kinetics revealed a peak 
immediately after the race that decreased rapidly 
to pre-test values within 72 h (median, 31.07 μg/L 
and 3.61 μg/L, respectively) in 102 healthy men 
(mean age, 42 ± 9 years). The authors stated that 
kinetics with a sharp peak indicate that cardiac 
necrosis during marathon running, though seem-
ingly very unlikely, are a function of altered myo-
cyte metabolism (34).
Data on professional cyclists during prolonged 
performances or by using Hs-cTnT are lacking. One 
study using a second-generation cTnI assay on 
trained male cyclists who simulated the 2007 Tour 
de France found a 30% increase in cTnI after the 
fi rst stage. The positive value percentage de-
creased until stage 12, when 50% of the sample 
showed positive values, and then peaked at stage 
15 (60%), before the positive values returned to 
30% at stages 17 and 18 (26). Positive values were 
measured in 6 out of 10 cyclists but were not ho-
mogeneously distributed over time, with some 
subjects showing only two positive values during 
the stage race, whilst others showed fi ve or more 
positive values. The highest number of positive 
values was recorded during the stages of the third 
week.
While troponin release during a 3-weeks stage 
race does not appear to be predictable, there is a 
rough relationship between its release and the de-
mand and technical diffi  culties of race stages. Our 
data confi rm this fi nding: while only one subject 
had detectable, but within range, TnT concentra-
tions at pre-race, we found only one positive value 
(> 0.010 μg/L) at half race and 3 out of 11 (23%) at 
the end of the race.
A study involving professional cyclists during a 
Giro d’Italia was performed using a fi rst-genera-
tion cTnT assay. In 25 athletes from fi ve diff erent 
teams, blood drawings were performed before the 
race and at 7, 14, and 21 days. Participant with-
drawals from the race and dropouts from the study 
reduced the fi nal study population from 17 to 10 
subjects. TnT was detected in 5 athletes, repeated-
ly in some cases, in a total of 10 samples out of 64, 
but without exceeding the cut-off  for assuming 
myocardial damage (18). In general, we can as-
sume that we observed similar results. However, 
the specifi city of the two assays is completely dif-
ferent, since skeletal troponin might have inter-
fered with the results obtained from the old assay. 
Moreover, a stable haematocrit was reported in 
that study (18), while plasma volume and conse-
quently haemodilution was observed in ours.
The data we obtained in professional cyclists dur-
ing a 3-weeks stage race hold particular interest 
and fi ll a gap in the current literature on cardiac 
markers during and after endurance exercise.
This is the fi rst study to describe the behaviour of 
cardiac stress markers in professional cyclists dur-
ing a 21-days stage race. The main fi nding is the 
evidence for an association between changes in 
cardiac biomarker concentrations (NT-proBNP and 
TnT) and net energy expenditure, and indirectly 
the metabolic eff ort spent during prolonged en-
durance performance.
The main limitation of our study resides in the 
small sample size. The number of subjects was dic-
tated by belonging to the team, collaborating in 
the study, other than being derived from a sample 
size calculation. Moreover, NSAIDs and antibiotic 
therapy was administered in three cases. Even if 
the treatment was specifi c for respiratory tract in-
fection and brief, a possible eff ect of NSAIDs on 
cardiac biomarkers cannot be ruled out. In conclu-
sion, elevated NT-proBNP during a 3-weeks cycling 
Biochemia Medica 2012;22(2):237-46
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stage race could be interpreted as an adaptation 
of the heart in response to stimulation by a very 
high workload and heavy and stressful exercise, as 
demonstrated by the increased energy expendi-
ture. The link between increased NT-proBNP and 
altered cardiac function, and the recovery of di-
astolic impairment described in prolonged cycling 
in particular, needs to be further explored.
Also, elevated troponin concentrations may result 
from the extreme eff ort involved during such an 
endurance sport event. Although the concentra-
tions of both biomarkers fell within the physiologi-
cal range, with only a few subjects exceeding the 
upper range limits, the possible event of transient 
overload, which must be recovered before exer-
cise is resumed, poses a health concern in individ-
uals with occult heart disease.
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Srčani indeksi, biološki biljezi srčanog oštećenja i potrošnja energije kod 
profesionalnih biciklista tijekom trotjedne etapne utrke Giro d’Italia
Sažetak
Uvod: Ispitivanje srčanog odgovora na napornu i kontinuiranu tjelovježbu ključno je za razumijevanje fi ziologije izdržljivosti. N-terminalni mož-
dani natrijuretski peptid (engl. N-terminal pro-brain natriuretic peptide, NT-proBNP) mogući je biljeg za praćenje opterećenja stjenke miokarda, 
a troponini (TnT i TnI) su u širokoj primjeni kod dijagnosticiranja srčane ishemije i infarkta miokarda. Uslijed naporne tjelovježbe mogu se razviti 
prolazna ishemija, opterećenje miokarda te dijastolička disfunkcija lijeve klijetke što potiče povećano stvaranje oba biološka biljega. Mjerili smo 
promijene koncentracija NT-proBNP i TnT kod vrhunskih biciklista tijekom trotjedne etapne utrke, kao primjera naporne tjelovježbe.
Materijali i metode: Ispitivanu je populaciju činilo 9 profesionalnih biciklista koji su sudjelovali na utrci Giro d’Italia. Prijeanalitička i analitička 
faza provedene su savjesno i pridržavajući se službenih preporuka. Bilježeni su antropometrički podaci, potrošnja energije i srčani indeksi (otkucaji 
srca, sistolički i dijastolički krvni tlak). Krv je sakupljena jedan dan prije utrke (dan -1), 12. i 22. dan utrke; analizom su utvrđene koncentracije NT-
proBNP i srčanog troponina T visoke osjetljivosti (engl. highly sensitive-troponin T, Hs-TnT) te je napravljena korekcija promjena volumena plazme.
Rezultati: Tijekom utrke se kod ispitanika snizio indeks tjelesne mase, a potrošnja energije se povećala za 52%. Koncentracije NT-proBNP su po-
rasle [dan -1: 23,52 ng/L (9,67-34,33); 12. dan: 63,46 ng/L (22,15-93,31); P = 0,039; 22. dan: 89,26 ng/L (34,66-129,78) prema danu -1; P < 0,001] 
i bile u korelaciji s otkucajima srca (r = -0,51; P = 0,006), sistoličkim krvnim tlakom (r = 0,39; P = 0,046) i potrošnjom energije (r = 0,70; P < 
0,001). Koncentracije TnT nisu varirale, no primijećena je proširena distribucija amplitude TnT.
Zaključak: Povećanja koncentracije NT-proBNP bila su u korelaciji s višom potrošnjom energije tijekom trotjedne biciklističke etapne utrke što bi 
moglo ukazivati na opterećenje miokarda.
Ključne riječi: N-terminalni moždani natrijuretski peptid; troponin T; fi zička izdržljivost; potrošnja energije
